Positron emission tomography clinical applications

Wolf AP, Fowler JS. Positron emission tomography. Biomedical research and clinical application. Neuroimaging Clin N Am 1995 5 87-101. 

M. Bergstrom, A. Grahnen, B. Langstrom, Positron emission tomography microdosing A new concept with application in tracer and early clinical drug development, Eur. J. Clin. Pharmacol. 59 (2003) 357-366. 

Three new positron emitting generator systems have been described. The practical availability of these radionuclides could significantly broaden the potential applications of positron emission tomography. The next few years should see human clinical trials undertaken to fully evaluate their utility for nuclear medicine. 

Column adsorbants, specifications and eluent solutions are discussed in determining generator performance for yield, breakthrough, and stability for long term use. Some examples of clinical applications in positron emission tomography are presented. 

Go RT, MacIntyre WJ, Chen EQ, et al. Current status of the clinical applications of cardiac positron emission tomography. Radiol Clin North Am 1995 32 501-520. 

Among the neutron-deficient isotopes of Tc, " Tc seems to have suitable nuclear properties for application in positron emission tomography (PET) (Browne and Firestone 1986). Considering the relatively new lipophilic Tc-labeled flow tracers used in cardiac perfusion imaging (2-methoxyisobutyl isocyanide [MlBl], teboroxime, tetrofosmin) it would be reasonable to replace Tc with " Tc in order to carry out quantitative investigations of biodistribution and clearance with PET. With this replacement, the pharmacokinetics of useful Tc compounds could be studied in a number of cases, which would enhance the introduction of new Tc-labeled pharmaceuticals into clinical practice. The labeling and quality control methods are well known and partly subject of this book. Our task is to review the different methods for the production of Tc and also the separation technique from irradiated targets. 

Pagani M, Stone-Elander S, Larsson S A (1997). Alternative positron emission tomography with non-conventional positron emitters effects of their physical properties on image quality and potential clinical applications. Eur. J. Nucl. Med. 24 1301-1327. 

Synthesis and pharmaceutical evaluation of positron emission tomography [ C] radiopharmaceuticals for the clinical application 06YZ737. 

The medical applications of radiotracers are further illustrated by positron emission tomography (PET). PET is used for clinical... 

Another important clinical application of HPAE-PAD is the determination of 2-deoxy-2-[ F]fluoro-D-glucose (FDG), which is the most widely used radiopharmaceutical for positron emission tomography (PET) studies. This approach is used in the diagnosis of a number of diseases and disorders including cancer, cardiovascular disease, and dementia [582,583]. In addition, it is an important tool in neuroscience to enable the study of brain regional activation [584] and in drug research where it is used to evaluate drug biodistribution. FDG is a... 

McQuade P, McCarthy DW, Welch MJ. Metal radionuclides for PET imaging. In Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography Basic Science and Clinical Practice. London Springer, 2003 251-264. Sun X, Anderson CJ. Production and application of copper-64 radiopharmaceuticals. Methods Enzymol 2004 386 237-261. 

---